EMA’s human medicines committee (CHMP) September meeting highlights
In its most recent meeting, the CHMP recommended nine new medicines and concluded its review of Vaxzevria’s thrombosis risk.
List view / Grid view
In its most recent meeting, the CHMP recommended nine new medicines and concluded its review of Vaxzevria’s thrombosis risk.
The FDA has granted fast track designation for Pfizer and Eli Lilly’s tanezumab for the treatment of chronic pain in patients with osteoarthritis...
19 January 2017 | By Niamh Marriott, Digital Editor
This transaction will be acting to enhance Lilly's existing portfolio in pain management for migraine, while adding a potential near-term launch...
25 March 2015 | By Victoria White
Pfizer Inc. and Eli Lilly and Company have announced that they are preparing to resume the Phase 3 clinical programme for tanezumab...